Peptides DB
Research-centric peptide and protocol reference hub
NPRNovember 9, 2026

An ‘Ozempic baby boom’? The GLP-1 pregnancy plot twist : Short Wave

Reported by NPR. Read the original →

What the story says

The headline suggests a connection between Semaglutide, commonly known as Ozempic, and an increase in pregnancies, referred to as an "Ozempic baby boom." It implies that there may be unexpected implications of GLP-1 receptor agonists on fertility or pregnancy rates.

Summarised by a model from NPR's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.

On file here

Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.

What the headline doesn't tell you

  • Semaglutide has 62 studies on file, 34 of them in humans, the newest published 2026.
  • This story is about a class — GLP-1 and incretin therapies — rather than one compound. We track 14 compounds in it, holding 373 studies between them, 163 in humans.

Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.